National Institute of Allergy and Infectious Diseases
  National Institutes of Health
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

Biodefense and Related Programs
 Biodefense
  About
  For Researchers
   Introduction
   Resources
   Funding
    FY2003 Awards
    FY2004 Awards
    FY2005 Awards
    FY2006 Awards
    FY2007 Awards
   Meetings
   Category A-C Pathogens
  Public and Media
 Radiation Countermeasures
 Chemical Countermeasures



Biodefense

Challenge Grants: Biodefense and SARS Product Development

FY 2004 Awards

Institution PI Name Title
Active Pass Pharmaceuticals, Inc. Ian MacDonald Development of Alphavirus Replicon Vaccine Against SARS
Affymetrix, Inc. Carsten Roseno Pathogen and Genetic Element Detection Using Microarrays
Alphavax Human Vaccines, Inc. Jonathan Smith Development of Alphavirus Replicon Vaccine Against SARS
BD Diagnostics Tobin Hellyer BD ProbeTec ET for Diagnosis of Influenza and SARS
Biota Scientific Management Jane Ryan Novel Influenza Biodefense Therapeutic and Prophylactic
Chiron Corporation John Polo Development of a SARS Coronavirus Vaccine
Columbia University Health Sciences W. Ian Lipkin Mass Tag PCR Detection of Respiratory Pathogens
Delsite Biotechnologies Yawei Ni An Inactivated Influenza Nasal Powder Vaccine
Dor Biopharma, Inc. Robert Brey Development of a Recombinant Vaccine for Ricin Toxin
Dynport Vaccine Company, LLC Ian Henderson Vitrification-stabilized Multivalent Botulinum Vaccines
Dynport Vaccine Company, LLC Donald Fine Phase 2 Trial for Venezuelan Equine Encephalitis V3526
Elusys Therapeutics Linda Nardone Monoclonal Antibody for Treatment of Inhalation Anthrax
Hawaii Biotech, Inc. Carolyn Weeks-Levy Clinical Development of a Dengue Vaccine
ID Biomedical Corporation of Northborough Jonathon Seals Novel cell-culture derived split influenza vaccine
ID Biomedical Corporation of Washington David Burt Development of Proteosome-adjuvanted nasal SARS vaccines
ID Biomedical Corporation of Washington George Lowell Development of ProtollinTM Plague Vaccine
K.U. Leuven Universiteitshal Johan Neyts Novel inhibitors of the replication of poxviruses
Medarex, Inc. Israel Lowy Fully Human Anti-Anthrax Toxin MAbs: Product Development
North Shore - Long Island Jewish Research Institute Howard Trachtman Human monoclonal antibody therapy for HUS
Sequella, Inc. Carol Nacy Advancing a new TB drug through early clinical trials
Transtech Pharma, Inc. David Ward Development of Protease Inhibitor to Treat Smallpox
University of Texas, Austin Steven Kornguth Diagnostics for Bacterial/Viral Pathogens Including SARS
University of Texas Medical Branch, Galveston Clarence Peters Rift Valley Fever Virus MP-12 Vaccine Completion
Weill Medical College of Cornell University Carl Nathan Dihydrolipoamide Acyltransferase:Target for Chemotherapy
Weill Medical College of Cornell University Francis Barany Multiplexed Detection of Bioterror Agents

back to top